Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AN 788

Drug Profile

AN 788

Alternative Names: AN-788; IP-2018; NSD788

Latest Information Update: 26 Sep 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator NeuroSearch
  • Developer Aniona; Initiator Pharma; Saniona
  • Class Antidepressants; Anxiolytics
  • Mechanism of Action Dopamine uptake inhibitors; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Erectile dysfunction
  • No development reported Major depressive disorder
  • Discontinued Anxiety disorders

Most Recent Events

  • 26 Sep 2022 AN 788 is still in phase-II clinical trials for Erectile dysfunction (In adults) in United Kingdom (unspecified route) (EduraCT2020-000469-18) (NCT04686916)
  • 26 Jun 2020 Phase-II clinical trials in Erectile dysfunction (In adults) in United Kingdom (unspecified route) (EduraCT2020-000469-18) (NCT04686916)
  • 08 Nov 2018 Saniona enters into a option agreement with Initiator Pharma for rights to acquire AN 788
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top